Chronic ecstasy use increases neurotrophin-4 gene expression and protein levels in the rat brain

Hatami, H.; Hossainpour-Faizi, Mohammad Ali; Azarfarin, Maryam; Azarfam, Parvin

doi:10.1016/s1734-1140(10)70361-3

Cited by 10 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gene sequences were obtained from Ensembl database (http://useast.ensembl.org/) which was also used to examine the genomic structure of genes and their transcripts. Primer sequence for Ps-1 was obtained following previous studies (Ricceri et al, 2004) and β-actin was selected as reference gene for gene expression analysis (Yamada et al, 2005;Soria-Fregoso et al, 2008;Hatami et al, 2010;Blanco et al, 2012). Primers covered at least two exons or were designed to amplify exons separated by large introns to avoid false-positive amplification of contaminating genomic DNA in the experimental samples.…”

Section: Primer Designmentioning

confidence: 99%

Intracerebroventricular streptozotocin induces behavioral impairments and increases short-term C3 gene expression in the hippocampus of Wistar rats

Pfutzenreuter¹,

Nieradka²,

Pincerati³

et al. 2020

Acta Neurobiologiae Experimentalis

View full text Add to dashboard Cite

A non-transgenic rat model based on intracerebroventricular injection of streptozotocin (STZ) has been used as an animal model to investigate mechanisms associated to the late onset of sporadic Alzheimer's disease, such as anatomical and behavioral impairments. However, molecular aspects related to gene expression, mainly in the hippocampus, require more investigation. Thus, this study evaluated the early and late cognitive functions and hippocampal gene expression after STZ administration. Male Wistar rats were divided into 4 groups: STZ (injected bilaterally), control group for the early memory function evaluation (1 month after surgery = phase 1, same volume of vehicle), and the same treatment for the late memory function evaluation (4 months after surgery = phase 2). The animals were observed in the elevated plus maze to assess behaviors related to anxiety, risk-assessment and fear-related memories. The behavioral tests were followed by brain removal and hippocampal dissection for RNA extraction and qRT-PCR to assess the expression levels of 4 Alzheimer's disease related genes: Mapt, Apoe, C3 and Ps-1. Animals from both phases showed increased time percentage and number of entries into the open arms, indicating risk behavior associated with anxiety, and an increased time percentage in the center square for both exposures (re-test) when compared to the control group, suggesting working memory impairment related to an aversive event. Statistical analyses indicated that the STZ group presented alterations in anxiety, memory and risk assessment responses. Additionally, one month after STZ administration, C3 gene assays revealed an increased expression. Therefore, current data indicate that neuroinflammatory events linked to the expression of pro inflammatory cytokines such as C3 are related to memory, anxiety and decision-making alterations.

show abstract

Section: Primer Designmentioning

confidence: 99%

Intracerebroventricular streptozotocin induces behavioral impairments and increases short-term C3 gene expression in the hippocampus of Wistar rats

Pfutzenreuter¹,

Nieradka²,

Pincerati³

et al. 2020

Acta Neurobiologiae Experimentalis

View full text Add to dashboard Cite

show abstract

“…DOI treatment (or immobilization stress) regulates neocortical Arc mRNA expression through BDNF signaling (Benekareddy et al, 2013). Chronic MDMA treatment increased NT-4 gene expression in the brain stem, cerebellum, and cerebral hemispheres of rats (Hatami et al, 2010).…”

Section: Action Of Substituted Amphetamines and Cathinonesmentioning

confidence: 99%

Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse

Korpi¹,

Hollander²,

Farooq

et al. 2015

Pharmacol Rev

125

View full text Add to dashboard Cite

“…L'administration chronique (5 jours) de MDMA augmente les niveaux de NT-4 dans le cerveau (Hatami et al, 2010). De plus, les consommateurs réguliers présentent une élévation de leur niveau sérique de BDNF, mais pas de NGF (Angelucci et al, 2010).…”

Section: 4-méthylènedioxyméthamphétamine Et Neurotrophinesunclassified

Utilisation des psychédéliques en psychiatrie : lien avec les neurotrophines

Corne

Mongeau

2019

Biologie Aujourd’hui

View full text Add to dashboard Cite

Reçu le 29 avril 2019Résumé --Les psychédéliques, souvent appelés hallucinogènes, sont une classe de psychotropes très singulière. Les effets subjectifs et comportementaux qu'ils induisent sont très impressionnants, et malgré leur toxicité potentielle, le risque d'addiction est relativement faible par rapport à la nicotine, l'alcool ou les opiacés. Depuis la découverte des effets antidépresseurs de la kétamine, il existe un regain d'intérêt pour cette classe de molécules. En effet, la psilocybine et l'acide lysergique diéthylamide (LSD) gagnent de la popularité en tant que traitement pour la dépression et l'addiction, la 3,4-méthylènedioxyméthamphétamine (MDMA) pour l'état de stress post-traumatique, et l'ibogaïne pour l'addiction. Malgré des profils pharmacologiques distincts, ces différentes drogues partagent une cinétique d'action similaire : leurs effets thérapeutiques se font ressentir dans les heures suivant l'administration et perdurent au-delà de leur élimination par l'organisme. Ceci suggère des mécanismes plastiques et neurogéniques impliquant entre autres des facteurs trophiques. Cette revue explorera la littérature concernant les effets de ces différents composés sur les neurotrophines, ainsi que les adaptations plastiques qui sont mises en place dans les heures et jours suivant l'administration, afin de comprendre leur potentiel thérapeutique étonnant. Abstract --Neurotrophic mechanisms of psychedelic therapy. Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and behavioral effects they induce are quite dramatic, they possess little addictive potential when compared to nicotine, alcohol or opiates. Since the discovery of ketamine antidepressant effects, there has been growing interest for these molecules. Serotonergic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) are gaining attention as potential treatments for depression and addiction, similarly to 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD), and ibogaine for addiction. Although they possess distinct pharmacological profiles, their kinetics of action are quite similar: the therapeutic effects are felt within the hours following administration, and last well beyond drug elimination by the organism. This strongly suggests the induction of neurogenic and plastic mechanisms, including the involvement of trophic factors. This review will explore the literature dealing with the effects of psychedelics on neurotrophins, as well as the plastic adaptations that they induce, in an attempt to understand their surprising therapeutic potential. We will show that although ketamine and serotonergic psychedelics have affinity for very different receptors (NMDA, 5-HT2A), they ultimately initiate similar plastic adaptations in the prefrontal cortex through the involvement of the brain-derived neurotrophic factor (BDNF). We will see that although MDMA uses the same receptors as serotonergic psychedelics to alleviate P...

show abstract

Chronic ecstasy use increases neurotrophin-4 gene expression and protein levels in the rat brain

Cited by 10 publications

References 33 publications

Intracerebroventricular streptozotocin induces behavioral impairments and increases short-term C3 gene expression in the hippocampus of Wistar rats

Intracerebroventricular streptozotocin induces behavioral impairments and increases short-term C3 gene expression in the hippocampus of Wistar rats

Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse

Utilisation des psychédéliques en psychiatrie : lien avec les neurotrophines

Contact Info

Product

Resources

About